Drug rebates were associated with higher out-of-pocket costs for patients

By | June 16, 2021
Federal agencies that regulate drug pricing and healthcare insurance are concerned that an industry practice of using rebates to lower drug costs for insurers has led to increases in list prices and out-of-pockets costs for patients.